Phage Consultants

Executive Summary

Phage Consultants is a Polish contract research organization (CRO) founded in 2010, specializing in bacteriophage therapy development and manufacturing. Operating in Gdańsk, the company supports the growing field of phage-based antimicrobials amid rising antimicrobial resistance. With a focus on infectious disease and microbiome applications, it likely provides services such as phage isolation, characterization, formulation, and GMP production to academic and biotech partners. As a privately held entity with no disclosed funding rounds or pipeline, its market visibility is limited despite the increasing regulatory and clinical interest in phage therapy in Europe. Recent moves by the European Medicines Agency to establish a regulatory framework for phage therapy could serve as a tailwind, but the company's impact remains tied to client successes. Given the niche nature of the business and lack of public metrics, the conviction in near-term value creation is modest.

Upcoming Catalysts (preview)

• 2026Announcement of new partnership or client contract for phage development60% success
• 2026Publication of EU regulatory guidance on phage therapy adoption70% success
• 2027Disclosure of service expansion or capacity investment (e.g., GMP facility)30% success